DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1


Por: Huertas-Martinez, J, Court, F, Rello-Varona, S, Herrero-Martin, D, Almacellas-Rabaiget, O, Sainz-Jaspeado, M, Garcia-Monclus, S, Lagares-Tena, L, Buj, R, Hontecillas-Prieto, L, Sastre, A, Azorin, D, Sanjuan, X, Lopez-Alemany, R, Moran, S, Roma, J, Gallego, S, Mora, J, del Muro, XG, Giangrande, PH, Peinado, MA, Alonso, J, de Alava, E, Monk, D, Esteller, M and Tirado, OM

Publicada: 1 feb 2017
Resumen:
Epigenetic modifications have been shown to be important in developmental tumors as Ewing sarcoma. We profiled the DNA methylation status of 15 primary tumors, 7 cell lines, 10 healthy tissues and 4 human mesenchymal stem cells lines samples using the Infinium Human Methylation 450K. Differential methylation analysis between Ewing sarcoma and reference samples revealed 1166 hypermethylated and 864 hypomethylated CpG sites (Bonferroni p < 0.05, delta-beta-value with absolute difference of >0.20) corresponding to 392 and 470 genes respectively. Gene Ontology analysis of genes differentially methylated in Ewing sarcoma samples showed a significant enrichment of developmental genes. Membrane and cell signal genes were also enriched, among those, 11 were related to caveola formation. We identified differential hypermethylation of CpGs located in the body and S-Shore of the PTRF gene in Ewing sarcoma that correlated with its repressed transcriptional state. Reintroduction of PTRF/Cavin-1 in Ewing sarcoma cells revealed a role of this protein as a tumor suppressor. Restoration of caveolae in the membrane of Ewing sarcoma cells, by exogenously reintroducing PTRF, disrupts the MDM2/p53 complex, which consequently results in the activation of p53 and the induction of apoptosis. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Filiaciones:
Huertas-Martinez, J:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Court, F:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Epigenet & Biol Programme PEBC, Barcelona 08908, Spain

Rello-Varona, S:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Herrero-Martin, D:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Almacellas-Rabaiget, O:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Sainz-Jaspeado, M:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Garcia-Monclus, S:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Lagares-Tena, L:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Buj, R:
 Inst Germans Trias & Pujol, Program Predict & Personalized Med Canc IMPPC, Barcelona 08916, Spain

Hontecillas-Prieto, L:
 Inst Biomed Sevilla IBiS, Lab Mol Pathol, Seville 41013, Spain

Sastre, A:
 Hosp Univ La Paz, Unidad Hematol & Oncol Pediat, Madrid, Spain

Azorin, D:
 Hosp Infantil Univ Nino Jesus, Serv Anat Patol, Madrid 28009, Spain

Sanjuan, X:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

 Hosp Univ Bellvitge, Dept Pathol, Barcelona 08908, Spain

Lopez-Alemany, R:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

Moran, S:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Epigenet & Biol Programme PEBC, Barcelona 08908, Spain

Roma, J:
 Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Res Inst, Lab Translat Res Pediat Canc, Barcelona 08035, Spain

Gallego, S:
 Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Res Inst, Lab Translat Res Pediat Canc, Barcelona 08035, Spain

Mora, J:
 Hosp St Joan de Deu, Dev Tumor Biol Lab, Barcelona 08950, Spain

del Muro, XG:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain

 Inst Catala Oncol, Sarcoma Multidisciplinary Unit, Barcelona 08908, Spain

Giangrande, PH:
 Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA

:
 Inst Germans Trias & Pujol, Program Predict & Personalized Med Canc IMPPC, Barcelona 08916, Spain

Alonso, J:
 ISCIII, Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Madrid 28029, Spain

de Alava, E:
 Inst Biomed Sevilla IBiS, Lab Mol Pathol, Seville 41013, Spain

 Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Seville 41013, Spain

Monk, D:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Epigenet & Biol Programme PEBC, Barcelona 08908, Spain

Esteller, M:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Epigenet & Biol Programme PEBC, Barcelona 08908, Spain

 Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain

 Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain

Tirado, OM:
 Inst Invest Biomed Bellvitge IDIBELL, Sarcoma Res Grp, Barcelona 08908, Spain
ISSN: 03043835





Cancer Letters
Editorial
Elsevier BV, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND, Países Bajos
Tipo de documento: Article
Volumen: 386 Número:
Páginas: 196-207
WOS Id: 000392773500020
ID de PubMed: 27894957

MÉTRICAS